Paper Details

  1. Home
  2. Paper Details

Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial.

Author: DongZhao, JiFei, LiuHui, LuoGuogang, PanXiaoping, XuYuming, YangXiaosu, YuShengyuan, ZhongShiying, ZhouJiying

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Lasmiditan, a 5-HT1F receptor agonist, is a potential treatment for migraine. This post-hoc analysis of the CENTURION study demonstrates the safety profile of lasmiditan in a Chinese population.
Paper Details　
Original Abstract of the Article :
Label="INTRODUCTION">Lasmiditan is the first 5-HT<sub>1F</sub> receptor agonist with potential to address the huge unmet medical needs for the treatment of migraine in China. The CENTURION study was the first phase&#160;3 study of lasmiditan in Caucasian and Chinese patients with migraine. This post...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s12325-022-02291-2

データ提供：米国国立医学図書館（NLM）

Safety of Lasmiditan in Chinese Patients with Migraine

This research focuses on the safety profile of lasmiditan, a novel medication for the treatment of migraine headaches, in Chinese patients. Lasmiditan, a 5-HT1F receptor agonist, holds great promise for addressing the unmet needs of migraine sufferers in China and around the world. The authors conducted a post-hoc analysis of the CENTURION study, a large clinical trial that investigated lasmiditan's efficacy and safety in both Caucasian and Chinese patients. This analysis specifically examined the safety data from Chinese participants, providing valuable insights into the medication's tolerability in this population. The findings demonstrate a reassuring safety profile of lasmiditan in Chinese patients, offering hope for effective and well-tolerated migraine treatment.

A New Era of Migraine Treatment

This research reinforces the potential of lasmiditan as a safe and effective treatment option for migraine headaches in Chinese patients. The study's reassuring safety findings pave the way for broader adoption of lasmiditan, offering new hope for millions of migraine sufferers in China. This research underscores the importance of conducting rigorous clinical trials and analyzing data from diverse populations to ensure that medications are safe and effective for all.

Understanding Migraine

Migraine headaches are a debilitating neurological condition that affects millions of people worldwide. The development of safe and effective treatments is crucial for improving the quality of life for these individuals. This research provides valuable insights into the safety of lasmiditan, offering a new therapeutic option for Chinese migraine sufferers. It is important to consult with a healthcare professional to determine if lasmiditan is right for you, as individual responses to medications can vary.

Dr.Camel's Conclusion

This study provides valuable information on the safety of lasmiditan in Chinese patients with migraine. The reassuring findings suggest that lasmiditan could be a valuable treatment option for this population. This research underscores the importance of understanding the nuances of drug safety in diverse populations to ensure that medications are safe and effective for all.

Date :
  1. Date Completed 2022-10-04
  2. Date Revised 2023-06-22
Further Info :

Pubmed ID

36114949

DOI: Digital Object Identifier

10.1007/s12325-022-02291-2

Related Literature

Article Analysis
・Effects of lasmiditan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.